For the quarter ending 2025-09-30, AQST has $163,559K in assets. $167,668K in debts. $129,063K in cash and cash equivalents.
| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 129,063 | 60,536 | ||
| Trade and other receivables, net | 11,801 | 11,864 | ||
| Inventories | 7,884 | 8,125 | ||
| Prepaid expenses and other current assets | 2,925 | 1,196 | ||
| Total current assets | 151,673 | 81,721 | ||
| Property and equipment, net | 3,918 | 3,858 | ||
| Right-of-use assets, net | 4,769 | 4,911 | ||
| Other non-current assets | 3,199 | 3,208 | ||
| Total assets | 163,559 | 93,698 | ||
| Accounts payable | 10,865 | 11,951 | ||
| Accrued expenses | 5,128 | 5,001 | ||
| Lease liabilities, current | 601 | 570 | ||
| Deferred revenue, current | 1,092 | 1,092 | ||
| Liability related to the sale of future revenue, current | 1,000 | 1,000 | ||
| Royalty obligations, current | 561 | 364 | ||
| Loans payable, current | 6,327 | 3,177 | ||
| Total current liabilities | 25,574 | 23,155 | ||
| Notes payable, net | 29,940 | 31,843 | ||
| Royalty obligations, net | 23,948 | 22,711 | ||
| Liability related to the sale of future revenue, net | 61,977 | 61,924 | ||
| Lease liabilities | 4,508 | 4,668 | ||
| Deferred revenue, net of current portion | 19,663 | 19,935 | ||
| Other non-current liabilities | 2,058 | 2,052 | ||
| Total liabilities | 167,668 | 166,288 | ||
| Common stock, 0.001 par value. authorized 250,000,000 shares 121,658,113 and 91,413,742 shares issued and outstanding at september30, 2025 and december31, 2024, respectively | 121 | 99 | ||
| Additional paid-in capital | 410,908 | 327,003 | ||
| Accumulated deficit | -415,138 | -399,692 | ||
| Total stockholders deficit | -4,109 | -72,590 | ||
| Total liabilities and stockholders deficit | 163,559 | 93,698 | ||
Aquestive Therapeutics, Inc. (AQST)
Aquestive Therapeutics, Inc. (AQST)